Steve J. Millen

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Correction: Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.

Correction: Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.

Journal: Breast cancer (Tokyo, Japan)

Published: August 21, 2026

Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US.

Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US.

Journal: Journal of medical economics

Published: February 19, 2026

Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Journal: JCO global oncology

Published: January 30, 2026

Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

Journal: JCO global oncology

Published: October 22, 2025

Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.

Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.

Journal: Breast cancer (Tokyo, Japan)

Published: July 31, 2025

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.

Journal: Breast cancer research and treatment

Published: February 07, 2024

Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.

Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.

Journal: Current oncology (Toronto, Ont.)

Published: December 18, 2023

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer.

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer.

Journal: ClinicoEconomics and outcomes research : CEOR

Published: May 26, 2022

Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.

Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.

Journal: Journal of medical economics

Published: April 13, 2022

Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.

Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.

Journal: Breast cancer research and treatment

Published: November 18, 2020

Device-related atypical pressure ulcer after cardiac surgery.

Device-related atypical pressure ulcer after cardiac surgery.

Journal: Journal of wound care

Published: August 21, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026